Navigation Links
Biologics Don't Raise Cancer Risk in Rheumatoid Arthritis Patients
Date:10/28/2008

Review finds no connection between drugs that block tumor necrosis factor and malignancies

TUESDAY, Oct. 28 (HealthDay News) -- TNF-antagonists, drugs widely used to treat rheumatoid arthritis (RA), don't appear to cause cancer, say Spanish researchers who analyzed data on more than 4,000 RA patients treated with the biologics.

These drugs, which have been used since 1998 and given to more than 600,000 people worldwide, interfere with biologic substances that cause or worsen inflammation in RA patients. But it's been unclear whether blocking TNF (tumor necrosis factor) increases the risk of cancer, according to background information in an American College of Rheumatology (ACR) news release about the study.

Some studies have suggested an association between RA and certain types of cancer, including lung and blood cancers, but the reasons for this increased risk are uncertain.

The data in this new study came from a drug registry called BIOBADASER, established in 2001 for long-term follow up of the safety of biological therapies in RA patients. The 4,529 RA patients treated with TNF-antagonists were compared with RA patients who didn't receive the drugs.

After they adjusted for age, sex, and RA duration/activity, the researchers found that the rate of cancer in the TNF group was very close to that of the non-TNF group (0.92 percent). Based on this, they concluded that TNF use isn't associated with an increased risk of developing cancer.

"Despite foreseen fears, blocking the tumor necrosis factor does not make patients more prone to develop cancer. All on the contrary, blocking the inflammation cascade may help diminish the overall risk of cancer in these patients," Dr. Loreto Carmona, director of the research unit at the Spanish Foundation of Rheumatology, said in the news release.

The study was presented Monday at the ACR annual meeting, in San Francisco.

More information

The U.S. Agency for Healthcare Research and Quality has more about medicines for rheumatoid arthritis.



-- Robert Preidt



SOURCE: American College of Rheumatology, news release, Oct. 25, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
2. CalbaTech Reports That LifeStems Biologics License Has Been Renewed
3. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
4. Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
5. AstraZeneca - Biologics Day Interviews With Senior Management
6. In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market
7. Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohns Disease
8. Growing Link Between Diabetes and Periodontal Disease Focus of National Gathering for Health Care Leaders
9. Treating your periodontal pockets may benefit your pocket book
10. Ortho Organizers(R) Announces the Launch of the Ancor Pro(TM) Orthodontic Anchorage System Hands-on Course
11. Survey confirms Americans prefer root canal treatment by endodontists
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biologics Don't Raise Cancer Risk in Rheumatoid Arthritis Patients
(Date:3/24/2017)... ... 24, 2017 , ... Digital Scientists, a software innovation lab specializing in web ... Greenville, South Carolina location. The lab has set up shop at the ... working with South Carolina clients for years from our office here in Atlanta,” explains ...
(Date:3/24/2017)... ... 2017 , ... According to a new study by NCPA Senior Fellow John ... the rules Congress has directed the CBO to follow. The CBO itself previously recognized ... Yet, it estimates a reduction in employer-based coverage due to the GOP reform, which ...
(Date:3/24/2017)... ... 24, 2017 , ... The iaedp Foundation, the premier provider of educational programs ... suffering from the full spectrum of disordered eating, announced today that the 2017 Symposium ... all 50 states and several countries converged on the Green Valley Resort in Las ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred ... 2017. This sacred and spiritual journey during the Summer Solstice will also ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017 Today Stock-Callers.com have issued research ... Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences ... SSH ). These companies are part of the Healthcare sector, ... March 23 rd , 2017, with the NYSE Health Care ... care companies in the S&P 500 were down about 0.4% ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
Breaking Medicine Technology: